The global biologic imaging reagents market is anticipated to grow significantly over the forecast period. Biologic imaging reagents refer to substances used by researchers or medical practitioners to conduct diagnostic or research-based exercises. Biologic imaging reagents play a pivotal role in the field of healthcare and other life science industries. They provide significant assistance in the detection of biological processes at a molecular level. Moreover, these imaging reagents assist medical practitioners and physicians in obtaining diagnostic information for the detection and treatment of diseases especially in the field of cardiovascular, oncology, and neurology.
The high prevalence of cardiovascular diseases, neurological diseases, and cancer is the most important driving factor for this market. According to WHO, cardiovascular diseases are one of the leading causes of death. This coupled with the rising patient awareness levels will drive the growth of this market by causing a rise in the number of diagnostic procedures. Moreover, growing demand for diagnostic imaging devices such as MRI and x-ray devices induced by the introduction of digital and portable systems and the implementation of PACS (picture archiving and communication systems) will cause a surge in the demand for biologic imaging reagents.
The contrast reagents market is further segmented into MRI reagents, ultrasound reagents, and x-ray and CT reagents. This market is expected to lead the overall market in terms of share throughout the forecast period. The high volume of diagnostic procedures performed using x-ray devices, ultrasound and MRI and the rising popularity of these devices on account of the growing demand for point of care diagnostics and home healthcare markets attribute to the aforementioned fact.
The radiopharmaceuticals market holds immense growth opportunities and its market is expected to exhibit a double-digit growth rate during the forecast period. Growing research and development initiatives and increasing awareness levels about nuclear medicine account for this high growth rate.
North America dominates the market in terms of share owing to the presence of sophisticated healthcare infrastructure, high per capita healthcare expenditure, and patient awareness levels. However, the Asia-Pacific biologic imaging reagents market will grow at the highest rate during the forecast period. The presence of high unmet medical needs and growing economic growth supporting healthcare infrastructure improvement in countries such as India and China attributes to this fact.
This research study encompasses a competitive landscape of the biologic imaging reagents market. Revenue analysis, product benchmarking, and strategic developments of key market players such as Bayer Healthcare AG, Beckman Coulter Inc., Bracco Imaging, Cardinal Health, Johnson and Johnson, Philips Healthcare, Siemens Healthcare, and others are also provided in this report.
Grand View’s market research study takes a closer look at the biologic imaging reagents industry, providing a holistic perspective on market dynamics, patient preference and disease trends, supply, and demand. Our report deep-dives into the market and segments it on multiple levels and providing key insights on a macro as well as microenvironmental level. The study aims at providing granular information, regarding estimates and forecasts for key product segments including contrast reagents, radiopharmaceuticals, and optical imaging reagents. The report analyzes the market for all the aforementioned product segments on a regional basis. Major geographies accounted for in this research study include NorthAmerica, Europe, and Asia-Pacific.
Grand View’s market research reports are developed using a 3600 methodology, which provides a balance between published authenticated data and exclusive primary research. We conduct exhaustive primary interviews with key industry participants, to enable readers to get a realistic feel of the industry pulse and facilitate decision making. Our unique excel-based reports not only provide key insights on the industry but also quick and easy data access, with enhanced usability at minimum effort. Grand View’s market research study attempts to provide insights to senior and top-level management, on critical industry questions such as the current and expected biologic imaging reagents global and regional supply-demand scene, drivers, restraints, opportunities and key trends in the market and how will these trends impact the market in coming years. Demand estimate and forecast for key product segments in the market, broken down by region have been provided in the study. The report also throws light on key industries for growth opportunities for biologic imaging reagent manufacturers and suppliers and the competitive landscape along with the market presence of key participants.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Amongst the majorly used Covid-19 screening options, imaging is preferred by most healthcare professionals as it provides a primary diagnosis in a short time. All the imaging modalities including nuclear imaging have been used exhaustively to study Covid-19 and its effect on different patients in each demography. These are used in theories such as comparison of the vulnerability of pediatric and geriatric patients, and treatment response for several drug combinations. The rising requirement for advanced lung imaging solutions is expected to boost the development studies for lung phantoms. A detailed study on lung deterioration in Covid-19 patients is expected to provide advanced measures for early detection of the disease. The report will account for Covid19 as a key market contributor.